JAK1 Inhibitor Shows ‘Remarkable’ Activity in T-Cell Lymphoma
Treatment with a novel, oral JAK1 tyrosine kinase inhibitor induced rapid and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), findings from a single-arm phase II study showed. Among 88 heavily pretreated patients evaluable for efficacy, 44% (95% CI 34-55) responded to single-agent golidocitinib, with 24% (95% CI 15-34) achieving a […]
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer
SAN ANTONIO — Bilateral mastectomy as initial treatment for women with breast cancer and a pathogenic BRCA1 variant was not linked to better survival, according to an international analysis. Compared with breast-conserving treatment (BCT), bilateral mastectomy was not significantly associated with a reduction in mortality in this population of patients (HR 0.83, P=0.52), reported Kelly […]
Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer
WASHINGTON — Treatment with cretostimogene grenadenorepvec, an investigational intravesically delivered oncolytic immunotherapy, achieved high response rates in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG), according to an interim analysis of the phase III BOND-003 trial. Among 66 patients evaluable for efficacy, 75.7% (95% CI 63-85) achieved a complete response (CR) […]
Very Young Children in HIV Treatment More Likely to Die
Children younger than age 5 years with HIV who received antiretroviral treatment (ART) died globally at percentages two to nine times higher than older children, a CDC study found. Among children receiving ART for HIV through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), 4.9% of those under age 1 and 2.5% of those […]
Noninvasive Therapy Shows Efficacy in Non-Muscle-Invasive Bladder Cancer
WASHINGTON — An investigational non-surgical treatment led to a “robust” complete response rate in patients with recurrent, low-grade non-muscle-invasive bladder cancer, the phase III ENVISION study showed. Patients treated with the UGN-102 (mitomycin) intravesical solution achieved a complete response rate of 79.2% (95% CI 73.5-84.1) at 3 months without having to undergo transurethral resection of […]
Clinical Challenges: Sequencing in Metastatic TNBC
As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnoses, but that proportion shrank with the new HER2-low designation, which accounts for approximately one-third of patients diagnosed with TNBC. An […]
Clinical Challenges: Test Your Knowledge on New Breast Cancer Treatments
The number of available treatment options for patients newly diagnosed with breast cancer continues to grow. The following three-question quiz will test one aspect from each article in our “Clinical Challenges” series on advanced breast cancer, which covered managing adverse effects of novel therapies and sequencing of treatments in metastatic HER2-positive breast cancer and metastatic […]
Clinical Challenges: Sequencing in Metastatic, HER2-Positive Breast Cancer
In the last few years there has been tremendous progress in the treatment of metastatic HER2-positive breast cancer. “We are getting a lot of therapeutic options coming into this space,” said Shridar Ganesan, MD, PhD, a physician-scientist at the Rutgers Cancer Institute of New Jersey. “Trastuzumab [Herceptin] was the first, but we now have a […]
Opinion | Proposed Methadone Treatment Legislation May Put Patients at Risk
Isherwood is an addiction specialist and medical director of an opioid treatment program. Overdoses in the U.S. due to opioids are hitting devastating new levels as high-potency synthetic opioids like fentanyl and metonitazene rack the nation. Medication-assisted treatment (MAT) for opioid use disorder is a life-saving intervention with unmatched success in patient outcomes. This typically […]
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
NASHVILLE, Tenn. — Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer’s immunity cycle to inform development of more effective therapies, according to a review presented here. Limited options exist beyond anti-VEGF and ICI-based strategies for patients with advanced disease, particularly those […]